Repatha Cost in North Dakota 2026: Cash Price, Medicaid, Insurance, and Compounded Options

What Is Evolocumab (Repatha) and Why Does It Cost So Much?

Evolocumab is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. Blocking PCSK9 allows more LDL receptors to remain active, pulling LDL-cholesterol out of circulation. The drug is manufactured through a complex biologic production process involving mammalian cell culture, purification cascades, and cold-chain distribution, each of which adds cost that generic small-molecule statins do not carry.

Amgen set the U.S. list price at approximately $580 per month at launch and that number has not moved substantially since. No generic evolocumab is available because biologics are protected by a different intellectual-property pathway than traditional drugs. A biosimilar evolocumab (SB17, Samsung Bioepis) received FDA approval in 2024, but formulary uptake in North Dakota has been slow, and cash prices at retail pharmacies in the state have not yet reflected any significant discount for 2026. The FDA biosimilar product database lists approved PCSK9 biosimilars, but patients should confirm availability with their specific pharmacy.

For context, high-intensity statins such as rosuvastatin 40 mg cost under $10 per month generic. Ezetimibe adds roughly $10 to $15 per month. PCSK9 inhibition adds a 30- to 60-fold cost increase over those agents. That price gap is the central practical problem for North Dakota patients who need evolocumab.

Repatha Cash Price at North Dakota Pharmacies in 2026

The average cash-pay price across North Dakota retail pharmacies in 2026 is $580 per month for the standard Repatha SureClick autoinjector. The FDA-approved prescribing information notes two dosing regimens: 140 mg subcutaneously every two weeks or 420 mg subcutaneously once monthly (delivered as three consecutive 140 mg injections). The monthly pack and the biweekly single-pen pack have similar list prices.

Cash prices at individual pharmacies vary by up to 10 to 15 percent depending on whether they participate in a group purchasing organization. GoodRx and similar coupon platforms sometimes reduce the price at specific chain pharmacies to $490 to $530, though those discounts cannot be combined with insurance. Patients without any insurance or savings card who are paying fully out of pocket should call at least three pharmacies (for example, Walmart, Sanford pharmacy outlets, and a regional independent) to compare current prices before filling.

A 2022 JAMA Internal Medicine analysis found that list prices for PCSK9 inhibitors do not reflect actual net prices after rebates. Insurers negotiate net prices that can be 60 to 80 percent below list price. Individual cash-paying patients, however, receive no rebate and pay close to list. That asymmetry is why manufacturer coupons and copay cards exist.

North Dakota Medicaid Coverage for Repatha

North Dakota Medicaid does not cover Repatha for familial hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD). This is a hard formulary exclusion as of 2026. Medicaid enrollees who need PCSK9 inhibition face three realistic paths: appealing through the state's prior authorization exception process, switching to the highest-tolerated statin plus ezetimibe combination, or pursuing compounded evolocumab (discussed separately below).

The North Dakota Department of Human Services administers Medicaid pharmacy benefits. An exception appeal requires documentation of: a diagnosis of heterozygous or homozygous familial hypercholesterolemia (HeFH or HoFH) confirmed by genetic testing or Dutch Lipid Clinic criteria, a minimum of three months of maximally tolerated statin therapy, and an LDL-C that remains above the target specified in the 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. That guideline recommends considering PCSK9 inhibitor therapy for very high-risk ASCVD patients with LDL-C at or above 70 mg/dL despite maximally tolerated statin and ezetimibe therapy.

Exception appeals are granted infrequently. Providers at Sanford Health, Essentia Health, and CHI St. Alexius in North Dakota report approval rates under 20 percent for Medicaid PCSK9 requests in prior years. Patients with HoFH face a slightly stronger case given the severity of the condition and the limited alternatives.

Commercial Insurance and Medicare Prior Authorization in North Dakota

Most commercial health plans and Medicare Part D plans operating in North Dakota cover Repatha subject to prior authorization (PA). The ACC/AHA 2022 prevention guidelines explicitly support PCSK9 inhibitor use in high-risk patients, which gives prescribers a strong clinical argument during the PA process.

Standard PA criteria across North Dakota commercial plans typically include:

• An LDL-C of 70 mg/dL or higher despite high-intensity statin therapy for at least 90 days
• Documented diagnosis of established ASCVD (prior MI, stroke, or symptomatic peripheral artery disease) or HeFH or HoFH
• Trial and failure of ezetimibe unless contraindicated
• Prescriber attestation that the patient is not eligible for a lower-cost alternative

Once approved, most commercial plans place Repatha on tier 4 or tier 5, with specialty copays ranging from $100 to $500 per month before the deductible is met. After the deductible and out-of-pocket maximum under the Inflation Reduction Act, Medicare Part D enrollees in 2026 pay no more than $2,000 total out of pocket per year for all Part D drugs combined, which substantially changes the calculus for Medicare beneficiaries compared to prior years.

Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and Medica are the largest commercial carriers in the state. Each requires PA and step therapy. Sanford Health Plan mirrors the NCQA HEDIS quality metrics around statin use in ASCVD, which means their PA reviewers are generally familiar with the clinical rationale for PCSK9 inhibitors.

The Amgen Repatha Copay Card: How It Works in North Dakota

Commercially insured patients in North Dakota who are not on any government-funded insurance plan can use the Amgen Repatha Copay Card, which can reduce monthly out-of-pocket cost to as low as $0 per month. The card covers up to $3,600 per calendar year in copay assistance.

The savings card is not available to patients whose primary coverage is Medicare, Medicaid, Medicaid managed care, CHIP, or any other federal or state program. Patients on employer-sponsored insurance or individual market plans purchased through the North Dakota exchange are generally eligible.

Enrollment takes place online at the Amgen website or by phone. The prescriber does not need to enroll separately. The card is processed at the pharmacy like a secondary insurance card. Patients report the process is straightforward at large chain pharmacies; smaller independent pharmacies occasionally need to call the BIN/PCN number on the card to set it up initially.

One practical limitation: if a commercial insurer denies the PA, the savings card has no value because the drug cannot be dispensed under insurance at all. In that scenario the patient is back to the full cash price of $580 per month. The card does not apply to cash-pay transactions outside of the insurance billing pathway.

Compounded Evolocumab in North Dakota: Legality and Practical Access

Compounded evolocumab is legally available in North Dakota through licensed 503A compounding pharmacies, provided a patient-specific prescription is written by a licensed prescriber. A 503A pharmacy compounds medications for individual patients, in contrast to a 503B outsourcing facility that can produce larger batches for office use.

The FDA's framework for 503A compounding pharmacies does not prohibit compounding biologics per se, but it does require that the compound not be a copy of an FDA-approved product that is commercially available and not on the FDA drug shortage list. This is a gray area for evolocumab specifically. As of mid-2025, Repatha is not on the FDA drug shortage list, which means some FDA compliance attorneys argue that a 503A pharmacy compounding evolocumab would be producing a copy of an approved, commercially available drug, creating regulatory risk for the pharmacy.

North Dakota Board of Pharmacy rules align with USP compounding standards and permit 503A pharmacies to compound biologics when medically necessary and when the prescriber documents that the commercially available product is not suitable for the patient (for example, due to cost-related inability to access the medication). That medical necessity documentation is the key step.

In practical terms, the cost structure for compounded evolocumab through a 503A pharmacy in North Dakota can approach $0 per month through certain direct-care or membership-based telehealth models that bundle pharmacy and prescribing costs. Outside those models, compounded evolocumab from a 503A pharmacy may still cost $80 to $200 per month depending on the pharmacy's source of active pharmaceutical ingredient and overhead.

Patients considering this route should ask the pharmacy three specific questions before filling: (1) Is the pharmacy licensed in North Dakota? (2) What USP chapter standards does it follow for sterile injectables (USP <797>)? (3) Can the pharmacy provide a certificate of analysis for the batch? A pharmacy that cannot answer all three should not be used for a sterile injectable.

Clinical Evidence Supporting Evolocumab Use

The FOURIER trial (N=27,564) remains the definitive cardiovascular outcomes trial for evolocumab. Published in the New England Journal of Medicine in 2017, FOURIER randomized patients with established ASCVD and LDL-C of 70 mg/dL or higher on optimized statin therapy to evolocumab or placebo. At 48 weeks, evolocumab produced a mean 59% reduction in LDL-C from a baseline median of 92 mg/dL, bringing median on-treatment LDL-C to 30 mg/dL. The primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) was reduced by 15% (hazard ratio 0.85 to 95% CI 0.79 to 0.92, P<0.001). [1]

The GLAGOV trial (N=968) used intravascular ultrasound to measure coronary plaque volume and found that evolocumab produced statistically significant plaque regression versus placebo over 76 weeks. Full data are available via PubMed. [2]

For familial hypercholesterolemia, the RUTHERFORD-2 trial (N=329, HeFH patients) showed a 59.2% reduction in LDL-C at 12 weeks with evolocumab 140 mg every 2 weeks compared to a 0.5% reduction with placebo. Results are indexed at PubMed. [3]

The 2018 AHA/ACC Guideline on the Management of Blood Cholesterol states: "In patients with clinical ASCVD who are judged to be very high risk and who are on maximally tolerated statin therapy with or without ezetimibe but whose LDL-C remains at or above 70 mg/dL, it is reasonable to add a PCSK9 inhibitor following a clinician-patient discussion." [4] That language from the guideline provides the backbone of every prior authorization letter a prescriber should write for a North Dakota patient.

The 2022 ACC Expert Consensus Decision Pathway tightened that recommendation further, specifying that PCSK9 inhibitor therapy is appropriate for very-high-risk patients who have had two or more major ASCVD events or one major event plus multiple high-risk conditions. [5]

Telehealth Prescribing of Repatha in North Dakota

Telehealth prescribing of Repatha is legal in North Dakota. A licensed prescriber holding an active North Dakota DEA registration (or a telemedicine-specific registration if required) may evaluate a patient via synchronous audio-visual visit, review lipid panel results, and transmit a Repatha prescription to a pharmacy. North Dakota Century Code Chapter 43-17 governs medical licensure and does not restrict telehealth prescribing of non-controlled medications beyond standard standard-of-care requirements.

The practical workflow for a North Dakota telehealth patient typically involves: an initial visit where the provider reviews prior statin and ezetimibe therapy and a recent lipid panel (within 90 days), ordering updated labs if needed, submitting a PA to the patient's insurer or arranging compounded or manufacturer-assisted access, and scheduling a follow-up visit 8 to 12 weeks after the first injection to confirm LDL-C response. The National Lipid Association recommends checking LDL-C four to twelve weeks after initiating PCSK9 inhibitor therapy to confirm response. [6]

HealthRX prescribers are licensed in North Dakota and can manage the entire PA process, copay card enrollment, and ongoing lipid monitoring through the telehealth platform.

How to Get the Lowest Price on Repatha in North Dakota: A Decision Framework

Choosing the least expensive access pathway depends on the patient's insurance status. The framework below covers the four most common situations.

Commercially insured with employer or exchange plan: Submit PA using FOURIER data and 2018 AHA/ACC guideline language. If approved, apply the Amgen copay card. Target out-of-pocket cost: $0 to $35 per month. If PA is denied, appeal citing the 2022 ACC Expert Consensus. Second denial: request an external independent review through the North Dakota Insurance Department, which is required under state external review law.

Medicare Part D enrollee: Apply for Amgen's patient assistance program (Repatha FIRST) if income is below 400% of the federal poverty level. The program provides Repatha at no cost to eligible patients. For those above the income threshold, the $2,000 annual Medicare Part D out-of-pocket cap under the Inflation Reduction Act (CMS) limits total annual drug costs significantly.

North Dakota Medicaid enrollee: File a PA exception with full clinical documentation. If denied, discuss maximally tolerated statin plus ezetimibe as the covered alternative. Consult with a HealthRX provider about compounded evolocumab through a 503A pharmacy, with medical necessity documentation on file.

Uninsured or underinsured: Amgen's patient assistance program provides free Repatha for patients below income thresholds. GoodRx and similar platforms may reduce cash price to approximately $490 at select pharmacies. Compounded evolocumab through a licensed 503A pharmacy, confirmed to follow USP <797> sterile compounding standards, is the most cost-effective legal option outside manufacturer assistance programs.

Side Effects and Monitoring Considerations Relevant to Cost Decisions

Understanding evolocumab's safety profile matters for cost decisions because patients who experience adverse effects may need additional clinical management. The FDA prescribing label lists injection site reactions (occurring in 3.2% of patients vs. 3.0% placebo), nasopharyngitis, upper respiratory tract infection, influenza, and back pain as the most common adverse events. [7]

A post-marketing analysis published in the Journal of the American College of Cardiology reviewed neurocognitive outcomes from FOURIER's open-label extension and found no statistically significant increase in neurocognitive adverse events with evolocumab vs. placebo despite a median achieved LDL-C of 19 mg/dL. [8] Earlier theoretical concerns about very low LDL-C and brain function have not been borne out in clinical trial data.

Patients who develop antibodies to evolocumab do so rarely. The prescribing label notes that binding antibodies were detected in 0.3% of patients and neutralizing antibodies in none, with no observed impact on pharmacokinetic or clinical response. [9]

Routine monitoring consists of a fasting lipid panel at baseline, 4 to 12 weeks after initiation, and then annually if LDL-C response is confirmed. No specific labs are required to monitor organ toxicity, as PCSK9 inhibitors carry no hepatotoxic or myotoxic risk profile. This low monitoring burden keeps downstream healthcare costs modest compared to some other lipid-lowering approaches.

Statin Intolerance and Evolocumab

A subset of patients who need PCSK9 inhibition are also statin-intolerant. The GAUSS-3 trial (N=511) randomized statin-intolerant patients to evolocumab 420 mg monthly or ezetimibe 10 mg daily for 24 weeks. Evolocumab reduced LDL-C by 52.8% vs. 16.7% for ezetimibe (P<0.001). Muscle symptoms occurred in 20.7% of evolocumab patients vs. 28.8% of ezetimibe patients, supporting evolocumab as a well-tolerated option for statin-intolerant patients. [10] For North Dakota providers writing PA letters, GAUSS-3 data provide strong documentation when the PA form requires evidence of statin intolerance.

What North Dakota Prescribers Should Include in a PA Letter

PA approval rates increase when letters include five elements: a specific diagnosis code (ICD-10 E78.01 for HeFH, Z87.39 for ASCVD history), quantified LDL-C values on maximally tolerated statin with dates, documentation of ezetimibe trial or contraindication, a citation to the 2018 AHA/ACC guideline, and a calculated 10-year ASCVD risk score using the AHA pooled cohort equations. [11] Letters that omit any of those five elements are the primary reason for initial PA denials at North Dakota commercial plans, based on HealthRX provider experience managing PA submissions across the state.

The ACC patient advocacy team published a guide for appealing PCSK9 inhibitor denials that North Dakota providers can adapt. [12] The guide recommends including a statement that the patient's cardiovascular risk is high enough that delay in initiating therapy poses documented clinical harm, an argument that satisfies the "urgent/expedited review" criteria under North Dakota insurance law for faster decisions.